Neurogene Inc.
NGNE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404644
In the last 90 days, Neurogene Inc. insiders filed 0 open-market purchases and 2 sales; 111 institutions reported holding it in 13F filings for Q2 2026, worth $544.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $340.0K in total
- 2
- 13F holdersQ2 2026, +17 vs. previous quarter
- 111
- 13F valueReported value at the end of Q2 2026
- $544.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NGNE, Q2 2026
No superinvestor reported holding NGNE at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Neurogene Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 (view filing)9:08 PM ET | Jul 6-7 | 1 day | Cvijic Christine MikailPresident and CFO | SSale | −4.80K | $36.12 | −$173.4K | −5.4%84.0K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)6:42 PM ET | Jul 1-2 | 1 day | Cvijic Christine MikailPresident and CFO | SSale | −4.80K | $34.71 | −$166.6K | −5.1%88.8K after | 3 lots10b5-1 |
| May 8, 2026 (view filing) | May 6 | 2 days | Cvijic Christine MikailPresident and CFO | SSale | −9.60K | $31.26 | −$300.0K | −9.3%93.6K after | 2 lots10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Jordan JulieChief Medical Officer | SSale | −828 | $21.89 | −$18.1K | −6.2%12.5K after | 10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | McMinn RachelChief Executive Officer | SSale | −3.35K | $22.07 | −$74.0K | −0.2%1.34M after | 10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −2.56K | $21.62 | −$55.3K | −2.4%103.2K after | 10b5-1 |
| Mar 17, 2026 (view filing) | Mar 13 | 4 days | Cobb StuartChief Scientific Officer | SSale | −6.80K | $20.81 | −$141.4K | −18.2%30.5K after | 3 lots10b5-1 |
| Mar 17, 2026 (view filing) | Mar 13 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −4.04K | $20.81 | −$84.2K | −3.7%105.8K after | 3 lots10b5-1 |
| Mar 3, 2026 (view filing) | Feb 27 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −4.80K | $25.11 | −$120.5K | −4.2%109.8K after | 10b5-1 |
| May 15, 2025 (view filing) | May 14 | 1 day | Cobb StuartChief Scientific Officer | SSale | −6.80K | $15.15 | −$103.0K | −24.6%20.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Neurogene Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 1,717,127 | $54.0M | 4.44% | 00.0% | Unchanged |
| Casdin Capital, LLC | 1,545,361 | $48.6M | 2.43% | +125,000+8.8% | Added |
| Redmile Group, LLC | 1,412,199 | $44.4M | 2.98% | −47,400−3.2% | Reduced |
| RTW Investments, LP | 1,362,456 | $42.8M | 0.37% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 1,271,342 | $40.0M | 1.98% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,057,983 | $33.3M | 0.00% | +52,913+5.3% | Added |
| Baker Bros. Advisors LP | 991,691 | $31.2M | 0.16% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 818,706 | $25.7M | 0.05% | +100,317+14.0% | Added |
| Trails Edge Capital Partners, LP | 714,885 | $22.5M | 3.57% | −67,902−8.7% | Reduced |
| Toronto Dominion Bank | 681,337 | $21.4M | 0.04% | 00.0% | Unchanged |